ASCO26: Alicia Morgans, MD, MPH, ARACOG - Quiz - MDSpire

ASCO26: Alicia Morgans, MD, MPH, ARACOG

Dr. Alicia Morgans of Dana-Farber Cancer Institute reported at #ASCO26 that ARACOG found darolutamide was associated with less decline in cognitive testing than enzalutamide, which may help guide treatment choice.

  • July 1, 2026

Share

Original Source(s)

ASCO26: Alicia Morgans, MD, MPH, ARACOG

  • July 1, 2026

Related Content

Established and emerging prognostic factors in mycosis fungoides and Sézary syndrome

From voice biomarkers to telemedicine screening: developing and evaluating a voice-based AI model for laryngeal lesion detection using the Bridge2AI-Voice dataset

Therapeutic inhibition of RAS in non-small cell lung cancer